Smoothie King just launched its GLP-1 Support Menu with five specific smoothie blends to help support the journey of ...

Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

A study shows a 25.6 per cent decline in weight-loss surgeries as more Americans turn to GLP-1 medications like Wegovy and ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

The researchers found a 25.6% drop in people undergoing bariatric ... the number of patients who took a glucagon-like peptide 1, or GLP-1 medication for weight loss, surged by more than 130% ...

Biweekly GZR18 injections also led to a maximum weight loss of almost 12 pounds at 24 weeks, compared to just over seven pounds for semaglutide. Like other GLP-1 agonists, the most common side ...

Research led by a Northwestern Medicine team found that, despite higher upfront costs, bariatric surgeries offer two more quality years of life compared to GLP-1 therapies. The long-term cost ...